Zimbabwe has turned down a major US healthcare agreement worth $367m (£272m) over five years due to Washington's request for sensitive biological samples.
The decision became public after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative has since stated that the US was demanding access to genetic material for scientific study and commercial gain but was unwilling to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued talks to reach a agreement agreeable to both sides so the country's critical HIV programme can be sustained.
Wider Background
This development comes after a similar case in neighbouring Kenya, where a high court suspended a related health funding agreement after legal challenges were raised about the security of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to boost openness and responsibility.
According to statements, Sixteen nations in Africa have so far agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy through US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that provided information," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery with no assurance that the final treatments would be available to our citizens should a new disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining systems already set up via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome continued dialogue with our American counterparts on how subsequent co-operation could be designed in a way that honours the independence and interests of each country."
Health Experts Response
Medical experts expressed it recognised the government's concerns, but suggested that negotiations should continue considering a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where technical issues exist, such as those involving data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the continuing challenges between accepting crucial international aid and safeguarding a country's data in an increasingly interconnected world.